We apologize for the inconvenience

The people search feature on Superpages.com is temporarily unavailable. You can still search for people on yellowpages.com since Yellow Pages and Superpages are part of one company.

You will be automatically re-directed to People Search on yellowpages.com in .

Please note our privacy policy has changed. To view the policy, please go to https://corporate.thryv.com/privacy/

Details

General Info

Ernest “Chappie” Conrad, MD, is a professor in the Department of Orthopedic Surgery at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth). Shortly after completing his fellowship, Dr. Conrad moved to the University of Washington School of Medicine in Seattle. He made the move because he was able to treat sarcoma using chemotherapy which was a new idea and he believed was just the beginning of treating bone and soft tissue tumors. In Seattle, he set the standards for the world in assessing risk and response in sarcoma patients using positron emission tomography (PET) and set the standards for limb salvage surgery (skeletal bone in adults and children). Currently his interest includes finding new drugs for sarcoma treatment. Dr. Conrad’s research projects include multiple clinical studies in pediatric and adult tumors with a special interest in pediatric limb-sparing procedures, benign pediatric tumors, and soft-tissue sarcomas in adults. His research interests include the metabolic imaging of sarcomas, the clinical and biologic description of hereditary multiple exostoses, and the response associated with musculoskeletal transplantation. When he isn’t working, he devotes his time to his family.

HoursCLOSED NOW
Regular Hours:
Mon - Fri
Sat - SunClosed

Contact Info

Phone:

Main - 713-486-3550

Fax - 713-383-1473

Address:
5420 West Loop S Ste 2400 Bellaire, TX 77401

Reviews

Be the first to review!
Write a Review
Category
Physicians & Surgeons, Pediatrics-Orthopedics
Provided by
Data provided by one or more of the following: Thryv, Data Axle, Yext.